Trial Details

None
Basic Information
Clinical ID c2661
Identifier NL-OMON48064
Trial Title Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with loss of response - Immunix
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis);10017969;10003816
Interventions Addition of methotrexaat to anti-therapy (infliximab or adalimumab) according to standard care (first 12 weeks 25 mg/week, followed by 15 mg/week) or a lower methotrexaat dosing regime (first 12 weeks 25 mg/week, followed by 7.5 mg/week)
Participant Information
Sponsor Academisch Medisch Centrum
City -
Country/Region Netherlands
Enrollment Criteria
Sex Requirement NOT SPECIFIED
Age Requirement ADULT, ELDER, OLDER_ADULT
Study Design
Study Type Interventional
Phase Not Available
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -